By jurisdiction
United States (FDA)
Every compound we track that has a recorded status under United States (FDA). Tap a name for the full picture, including the U.S. status and primary sources.
| Compound | Status here | Note |
|---|---|---|
| AOD-9604 | In limbo | Removed from 503A Category 2 on Sep 27, 2024 after the nominations were withdrawn; PCAC voted 0-12 against the 503A list on Dec 4, 2024; in no category, not compoundable. |
| BPC-157 | In limbo | Not on the 503A Bulks List. PCAC recommended adding it on Jul 23, 2026 (8-6, 1 abstention); the recommendation is advisory and the FDA has not acted. |
| CJC-1295 | In limbo | Removed from Category 2 (~Sept 2024); PCAC voted against inclusion Dec 4, 2024; not on the 503A list; no USP monograph. |
| Dihexa | In limbo | Removed from 503A Category 2 on Apr 22, 2026 after the nomination was withdrawn; not on the 503A list; PCAC review expected before end of Feb 2027. |
| Emideltide (DSIP) | In limbo | Not on the 503A Bulks List. PCAC voted against adding it on Jul 24, 2026 (6-7, 1 abstention). No further FDA action is scheduled. |
| Epitalon | In limbo | Not on the 503A Bulks List. PCAC recommended adding it on Jul 24, 2026 (7-4, 1 abstention); the recommendation is advisory and the FDA has not acted. |
| GHK-Cu | In limbo | Topical route ≈ Category 1; injectable route removed from Category 2, not on the 503A list; PCAC review expected before end of Feb 2027. |
| Ipamorelin | In limbo | Removed from Category 2 (~Sept 2024); PCAC voted against 503A inclusion Oct 29, 2024; not on any bulks list; no separate ban. |
| KPV | In limbo | Not on the 503A Bulks List. PCAC recommended adding it on Jul 23, 2026 (8-6, 1 abstention); the recommendation is advisory and the FDA has not acted. |
| LL-37 (cathelicidin) | In limbo | Removed from 503A Category 2 on Apr 22, 2026 after the nomination was withdrawn; not on the 503A list; PCAC review expected before end of Feb 2027. |
| Melanotan II | In limbo | Not on Category 1 / the 503A list; being moved out of Category 2; PCAC review expected before end of Feb 2027. Not DEA-scheduled. |
| MOTS-c | In limbo | Not on the 503A Bulks List. PCAC recommended adding it on Jul 23, 2026 (7-5, 2 abstentions); the recommendation is advisory and the FDA has not acted. |
| NAD+ | In limbo | Proposed for non-inclusion (2019); no final rule and no ban; oral sold as a supplement; injectable compounded in a gray area. |
| Selank | In limbo | Removed from Category 2 (~Sept 2024); never in Category 1; not on the 503A list; no scheduled PCAC review. |
| Semax | In limbo | Not on the 503A Bulks List. PCAC recommended adding it on Jul 24, 2026 (8-5, 1 abstention); the recommendation is advisory and the FDA has not acted. |
| TB-500 (Thymosin Beta-4) | In limbo | Not on the 503A Bulks List. PCAC recommended adding it on Jul 23, 2026 (8-6, 1 abstention); the recommendation is advisory and the FDA has not acted. |
| Thymosin Alpha-1 | In limbo | Removed from Category 2 (Sept 2024); PCAC declined to recommend it on Dec 4, 2024; not on the 503A list; no approved U.S. product. |
| Cagrilintide | Restricted | Investigational; not approved, not compoundable (not a component of an approved drug, not an eligible bulk substance). The CagriSema NDA is under FDA review; warning letters to sellers, including products sold under coded names. |
| Kisspeptin-10 | Restricted | 503A Category 2 since Sep 29, 2023 - FDA would consider taking action against a pharmacy that compounds with it. PCAC voted 0-11 against adding it to the 503A bulks list (Oct 29, 2024); no final rule yet. No FDA-approved kisspeptin product. |
| PT-141 (bremelanotide) | Restricted | FDA-approved prescription drug: Vyleesi, NDA 210557, approved Jun 21, 2019. As a component of that drug it may be 503A-compounded for an individual patient, but not as regular copies of Vyleesi while it is marketed. Aug 24, 2026: FDA warning letters to five online “research peptide” sellers name PT-141. |
| Retatrutide | Restricted | Investigational; not approved, not compoundable (never on the shortage list, not an eligible bulk substance). FDA warning letters to sellers, including products sold under coded names. |
| Semaglutide (compounded) | Restricted | Enforcement discretion ended Apr 22, 2025 (503A, as announced; the FDA’s Sep 2026 Empower letter dates it Apr 24) / May 22, 2025 (503B); FDA proposed permanent 503B exclusion (Apr 2026). Narrow patient-specific 503A exception remains. Sep 18, 2026: FDA warning letter to Empower Pharmacy over semaglutide/B12 injections that appear to be essentially copies. |
| SS-31 (elamipretide) | Restricted | FDA-approved prescription drug: Forzinity (elamipretide hydrochloride) injection, NDA 215244, accelerated approval Sep 19, 2025. As a component of that drug, the HCl salt may be 503A-compounded for an individual patient, but not regularly or in inordinate amounts as essentially copies of Forzinity. FDA has called elamipretide (SS-31) acetate ineligible for 503A compounding (Dec 2025 warning letter). Not on any 503A category list. |
| Tesamorelin | Restricted | Approved Nov 10, 2010 (Egrifta); deemed a biologics license (BLA 022505) on Mar 23, 2020, so outside the 503A/503B compounding exemptions. Aug 24, 2026: FDA warning letters to five online “research peptide” sellers name tesamorelin. |
| Tirzepatide (compounded) | Restricted | Enforcement discretion ended Feb 18, 2025 (503A, as announced; the FDA’s Sep 2026 Empower letter dates it Mar 5) / Mar 19, 2025 (503B); FDA proposed permanent 503B exclusion (Apr 2026). Narrow 503A exception remains. Sep 18, 2026: FDA warning letter to Empower Pharmacy over tirzepatide/niacinamide injections that appear to be essentially copies. |
| Sermorelin | Compounding-legal | Not on the 503A bulks list or any interim category. Compounded as a component of Geref (NDAs 19-863, 20-443), whose approvals were withdrawn at the sponsor’s request effective Jun 18, 2009; FDA found (Mar 4, 2013) it was not withdrawn for safety or effectiveness. FDA has not addressed whether a withdrawn approval still qualifies. |